GSK Roundup: Whence The $3 Billion Figure As A China Fine
This article was originally published in PharmAsia News
A PharmaAsia News review of media reports finds the idea of China fining GlaxoSmithKline $3 billion for its alleged corruption was generated in offhand remarks at a press conference in July and not a figure ever put forth by Chinese authorities as under consideration.
You may also be interested in...
Demand for tele-diagnostic tools has reached unprecedented levels during COVID-19, said Kees Wesdrop, Royal Philips’ chief business leader of precision diagnosis.
Transparency On COVID Vaccine Clinical Holds Needed, Sharfstein Says; US FDA Advisory Cmtes Offer Venue
Former acting Commissioner Josh Sharfstein argues that while agency officials have done a commendable job in overall communication on COVID vaccine development, more information is needed on the clinical holds.
Trump administration effort to reduce drug prices by curtailing agency program requiring new approvals for some old products undermines FDA’s role in policing the safety of prescription drugs, experts say.